Background: Radiofrequency (RF) ablation is a well-established approach to treat
| INTRODUC TI ON
Premature ventricular contractions (PVC) are very common arrhythmias in clinical practice. Many patients with PVC experience a symptomatic progression of the disease with occurrence of other symptoms apart from palpitations such as dyspnoea, atypical precordial pain, dizziness, pre-syncope, or syncope.
Nowadays, radiofrequency (RF) ablation is a well-established approach to treat PVC and is associated with favorable outcomes and long-term results. 1 Pace mapping of ventricular tachycardia (VT) is performed by comparing the QRS morphology during overdrive pacing to that of the clinical tachycardia. Pace-mapping during sinus rhythm is an important tool during the ablation for monomorphic PVC. 2, 3 Radiofrequency has historically been guided by two-dimensional mapping and in recent years by three-dimensional mapping, with satisfactory safety and efficacy. 4 Recently, catheter contact force (CF) and PASO™ automated pace-mapping module have been developed This study sought to analyse the acute efficacy and 1-year outcome of PVC ablation using RF technology with an approach guided by PASO™ module and contact force.
| ME THODS

| Patient characteristics
Sixty-one consecutive patients (52.4% males, age 45.9 ± 12.5) underwent catheter ablation for symptomatic PVCs from February 2015 to March 2017. All patients were refractory to medical therapy by antiarrhythmic drugs, except one who stopped the treatment because of severe bradycardia. Eight patients (13.1%) had coronary artery disease; four patients (6.5%) had an implantable cardioverter-defibrillator (ICD). Fourty-seven patients (77.0 %) had a normal left ventricular (LV) function (>50%). In six patients (9.8%),
LVEF was slightly reduced (41%-50%), in six patients (9.8%) moderately reduced (31%-40%), and in two patients (3.3%) severely reduced (<30% All patients experienced failed attempts of antiarrhythmic medical therapy except one who presented severe bradycardia. Among patients who experienced a failure of antiarrhythmic therapy (n = 60), the majority were under beta-blockers (78.6%; n = 48), then calcium channel blockers were given in 24.5% of patients (n = 15), class III antiarrhythmic drugs were administered in 13.1% (n = 8) and class IC antiarrhythmic drugs were tried in 9.8% (n = 6). 
| Electrophysiology study and radiofrequency ablation
Electrophysiology study and ablation was performed in the fasting state, under conscious sedation. All patients had discontin- RF was started on the spots identified by PASO™ when stable catheter position with ≥10 g of CF were obtained.
| Template matching: the PASO™ module
Matching between paced beats and spontaneous PVC was automatically assessed using PASO™ software module. This software compares paced electrocardiograms to a maximum of 4 different acquired arrhythmia ECGs. An average correlation match value is assessed for each of the 12 ECG leads by calculating the area from baseline to the signal for the captured interval. Pace mapping was performed at the same cycle length than the coupling interval of the PVC and using a stimulation amplitude of 1 mA greater than the diastolic threshold. We considered as optimal pace-mapping presence of PASO™ mean correlation index ≥95% in the 12 lead, good pace-mapping as PASO™ between 90% and 94%, sufficient pace-mapping as PASO™ between 85% and 89%; no RF delivery was allowed in presence of PaSo <85%. In presence of PASO™ <95% RF ablation was performed on the site showing the best achievable electrograms (EGM) precocity around the region of the best Pacemapping.
Ablation was performed delivering RF energy using a power from 20 W up to 30 W, a temperature limit of 43°C and a set 17 ml/min cold saline flow. At successful RF ablation sites, energy delivery was continued for 90 seconds. When PVCs were not eliminated after 30 seconds, the energy delivery was terminated and another site was selected for remapping and ablation. The successful ablation site was defined as the elimination of PVC. After successful RF pulse, two further consolidation RF pulses were delivered for each patient.
| Definitions
The procedure was defined as acutely effective if the PVC disappeared during RF and did not recur within 30 minutes after last RF delivery. Recurrence of PVC within 24 hours post ablation was defined as acute failure. A decrease >95% in PVC burden at 1-year ECG Holter monitoring after ablation procedure, as compared to preablation ECG Holter, was defined as long-term effective. We defined cases with discrepancy as those showing precocity higher or lower than mean ± SD in Optimal and Sufficient Categories.
| Follow-up
All patients underwent 12-lead ECGs and 24-hours Holter monitoring during the 24 hours after the procedure. ECG, Holter monitoring and transthoracic echocardiography were performed during the follow-up at 1, 3, and 12 months after the ablation procedures.
Antiarrhythmic drugs were discontinued after the ablation if the procedure was successful. One-year follow-up data were available for all patients who had undergone successful ablation.
| Statistical analysis
Continuous variable are expressed as the mean ± standard deviation and compared using the T test; categorical variables are expressed as numbers and percentages and were compared using the chisquared test. Statistical significance was selected at a value of P < 0.05. 
| RE SULTS
| Baseline characteristics
The PVC ablation was performed in the right ventricular outflow Table 2 .
| Acute success
PVC ablation was acutely successful in 59 of patients (96.7%). In No further RF applications due to proximity (2 mm) of the distal tip of the ablation catheter to the left main coronary artery at coronary angiography.
High power setting was required to obtain acute procedural success in three cases. One was a 39-year-female, with a previous failed procedure, with PVC arising from the region of septal tricuspid annulus; power setting was increased to 40 W. Two cases with PVC originating from low voltage antero-septal scar area CF was >10 g but, to achieve acute success, power was increased up to 50 W.
No major procedure-related complications occurred in the study population; three (4.9%) patients showed minor vascular complications not requiring surgery.
| Predictors of acute success
PASO™ matching before RF delivery was 94.4 ± 2.9%. PASO was 96.8 ± 1.1% in Optimal pace-mapping sites, 93.0 ± 1.1% in good pace-mapping, and 91.8 ± 4.6% in sufficient pace-mapping sites (P < 0.001). EGM precocity was 39.6 ± 5.8 ms in the optimal pacemapping sites, 38.6 ± 5.9 ms in the good pace-mapping sites, and 36.5 ± 5.8 ms in the sufficient pace-mapping sites (P = 0.57) (Figure 2 ). Contact force was 17.7 ± 5.6 g in the optimal pacemapping sites, 16.6 ± 5.2 g in the good pace-mapping sites, and 19.4 ± 7.1 g in the sufficient pace-mapping sites (P = 0.34). RF was effective in 77.3% in sites with optimal pace-mapping; was 26.1% in sites with good pace-mapping efficacy, and it was 11.4% in sites with sufficient pace-mapping. In the effective ablation sites, the PASO™ matching was higher compared to ineffective sites (96.0 ± 2.8% vs 93.3 ± 2.5%, P < 0.01). Relationship between PaSo and efficacy, stratified for first RF application and later RF applications is shown in Figure S1 . EGM precocity at the activation map was 38.9 ± 6.0 ms; it was higher in effective than in ineffective sites (41.3 ± 5.9 ms vs 37.2 ± 5.5 ms, P = 0.003). Relationship between EGM precocity and efficacy, stratified for first RF application and later RF applications is shown in Figure S2 .
Ten ineffective RF pulses were delivered in sites showing Optimal pacemapping (PM), 65 in Good PM sites, and 31 in Sufficient PM sites. After successful RF pulse, two further consolidation RF pulses were delivered for each patient. Patients with ineffective RF pulses in optimal PM sites received further RF pulses in surrounding areas that resulted in PVC elimination. Those effective RF pulses showed F I G U R E 2 Pacemapping results, electrogram precocity, and acute efficacy in the study population. EGM precocity was 39.6 ± 5.8 ms in the optimal pacemapping sites, 38.6 ± 5.9 ms in the good pace-mapping sites, and 36.5 ± 5.8 ms in the sufficient pace-mapping sites. EGM precocity: Electrogram precocity slightly higher PASO™, without reaching statistical significance, as compared to ineffective ones.
We found one case with discrepancy in the Optimal PASO™ category: one RF pulse showed a precocity of 29 ms, despite a PASO™ of 97%; the RF pulse was successful. In the Sufficient PASO™ category we found two discrepancies: one showing a precocity of 44 ms, despite a PASO™ of 89%; the RF pulse was unsuccessful. One RF showed a precocity of 29 ms, despite a PASO™ of 87%, the RF pulse was unsuccessful. Relationship between PaSo and EGM precocity is shown in Figure S3 .
Based on ST analysis, a PASO™ >94 % was chosen as the best predictor of RF application efficacy. The other patient with PVC recurrence was affected by chronic ischemic cardiomyopathy; despite a sufficient PASO™, PVC recurrence with a similar morphology was recorded at 1-month Holter monitoring.
| Follow-up
| D ISCUSS I ON
The main findings of the present study are: (a) monomorphic PVCs ablation mainly guided by PASO™ and CF showed high success rate in both acute and 1-year follow-up (96.7% and 93.4%, respectively);
(b) PASO™ ≥95% was associated with acute PVC elimination in 77%
of cases.
| Added value of pace mapping and contact force
Catheter ablation of ventricular ectopy is traditionally based both on pace-mapping and activation mapping. Reports indicated that with pace mapping, the closer the pacing site from the tachycardia site of origin, the greater the similarity of the QRS morphology between the tachycardia and paced morphology. In a study by Kurosaki et al, 3 the template matching was shown to be a better discriminator than subjective scoring by experienced electrophysiologists. A template matching correlation of ≥90% predicted a successful ablation site with a sensitivity of 90%. In our study, both the acute and the 12 months follow-up success rates were high, with short fluoroscopy time and low rate minor complications.
Published detailed data on follow-up after ablation of PVC is limited, in particular using the technologies and algorithms available nowadays. Acute success in published series ranges between 77% 16 Low CF values during ablation in atrial fibrillation have been associated with higher recurrence rates. 17 Mizuno et al 18 showed that during ventricular substrate mapping a CF >8 g is a predictor of good contact with the tissue and is mandatory to correctly record low voltage components of ventricular electrograms.
In the present study an average CF of 18.3 g was used during the PVC ablation. The CF information may be useful to prevent complications because of excessive pressure on a thin myocardium, such as in the right ventricle, and also to create a more effective and durable lesion.
In presence of an optimal or good pace-mapping and persistence of the PVC after ablation, careful attention should be payed to CF monitoring during RF delivery; achievement of stable CF during ablation without PVC disappearance should prompt the suspect of deep origin of the PVCs that in some cases might be treated with high power RF settings (Figure 4 ).
In our study, the RF ablation was guided by CF sensing targeting minimum values of 10 g; although no complications occurred, no statistical inference can be done because of the small group of patients with PVC recurrence (n = 2) and the lack of a control group.
| Limitations
The most important limitation of this study is related to its retrospective design. In addition, being a single tertiary center study, results
should not be generalized. Other important limitations are the relatively low number of patients enrolled in the study because of the stringent inclusion criteria and the lack of a control group. PASO™ was used as the main guide for RF ablation; in presence of PASO™ >95%, EGM precocity was not considered in the decisional step.
| CON CLUS IONS
Premature ventricular contraction RF ablation mainly guided by PASO™ and CF showed high success rate in both acute and 1-year follow-up (96.7% and 93.4%, respectively) with a very low rate (4.9%) of minor complications. The best efficacy cut-off for RF ablation of PVCs has been identified in presence of both PASO™ ≥95%
and CF >10 g.
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